Great expectations have been dashed and heads have rolled at ValiGen N.V., which was founded less than two years ago in a highly promoted transnational merger between genotyping company ValiGene SA and genoplasty company Kimeragen Inc.

Not long after the merger in February 2000, the acquisition of Infogen Medizinische Genetik GmbH, which was developing a patient and phenotype profile database and tissue collections, seemed to add potency to an already fertile marriage.